Individual physiomarkers of levodopa-induced local field potential fluctuations interact with deep brain stimulation in Parkinson’s disease
Objective: We investigated the behavior of LFPs in 57 patients across therapeutic states using a data-driven method to find personalized physiomarkers. Background: The power of…Detection of α-synuclein Seeds in Skin and CSF Samples from PPMI Participants.
Objective: To compare the distribution of α-synuclein seeds (syn-seeds) between skin and CSF samples from PPMI participants, including prodromal, early Parkinson’s disease (PD), and late…Sleep-wake Alterations are Associated with a Decreased DTI-ALPS, a Marker of Perivascular Glymphatic Functioning, in Patients with Isolated REM Sleep Behavior Disorder
Objective: We aimed to explore circadian disruption in iRBD and its association with the Diffusion Tensor Imaging- ALong the Perivascular Space (DTI-ALPS) index, a proxy…Blood-based biomarkers for diagnosis and prediction of Parkinson’s Disease in GBA1 individuals
Objective: To investigate glucocerebrosidase (GCase) enzymatic activity and different forms of α-synuclein (aggregated -Asyna – and monomeric - Asynm) in peripheral blood mononuclear cells (PBMCs)…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy
Objective: We aimed to identify distinct plasma proteins in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA) and evaluate their associations with disease…Metabolomic breath landscape analysis unravels lipid biomarker candidates in patients with monogenic and idiopathic Parkinson’s disease
Objective: We propose an untargeted metabolomics approach using exhaled breath analysis to (1) characterize the non-volatile metabolomic breath signature of Parkinson’s disease (PD) patients with…Barriers to Healthcare Utilization and Adherence to Medications among People Living with Parkinson’s Disease in Senegal
Objective: To explore the barriers to healthcare utilization and adherence to medications among people living with Parkinson’s disease in Senegal, and propose context-informed strategies to…Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial
Objective: Evaluate the effects of BIIB122/DNL151 treatment on CSF levels of pRab10, a biomarker of CNS LRRK2 modulation, in a Phase 1 study in healthy…Investigation of cortex – basal ganglia pathways with cortical stimulation and subthalamic evoked responses in patients with Parkinson’s disease
Objective: To investigate the electrophysiological interplay between the human cortex and the subthalamic nucleus (STN) by comparing STN responses to direct cortical electrical stimulation and…
- « Previous Page
- 1
- …
- 374
- 375
- 376
- 377
- 378
- …
- 1942
- Next Page »